Eleven Biotherapeutics begins phase 3 trial for dry eye solution

A clinical-stage biopharmaceutical company announced Tuesday that it has begun patient randomization and dosing in the next phase of a study for a dry eye treatment.Eleven Biotherapeutics of Cambridge, Mass., is in the beginning stages of the company's first phase 3 clinical study of EBI-005, a topical ophthalmic solution, according to a press release.